- Date
- 24th Oct 2012 - 24th Oct 2012
- Location
- Hilton Zurich Airport Hotel, Opfikon-Glattbrugg (see on map below)
- Type
- Training
- URL
- view event website
- Organiser
- C.E.L.forpharma
- Contact
- Marie Stricklesse
- marie.stricklesse@celforpharma.com
- --
This is an introductory course and therefore very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries.
By attending this course, you will:
- Know what determines the value of life science biotechs and emerging pharma companies.
- Gain a thorough understanding of key valuation terms, concepts, tools & techniques.
- Learn and practice how to use a model that assesses the soft factors of a biotech company prior to its valuation.
- Learn and practice how to calculate the value of a biotech company.
- Learn and practice how to calculate the value of a development compound with an excel tool you can take home and use for any other pharmaceutical product in development.
- Learn and practice how to structure licensing deals between pharma and biotech, covering issues such as milestones and royalty payments.
- Learn and practice how to gain expert insight and advice from Patrik Frei and Johan Ohlsson who have assessed and valued numerous products and companies in the life sciences industry.
What sets the Pharma-Biotech Product & Company Valuation course apart?
The experts: Patrik Frei wrote the first book on the valuation of high-growth companies, including biotech and other life science companies. Patrik and Johan are reputable specialists in the valuation of life science companies, with in-depth insight into the Venture Capital, Pharma and Biotech sectors.
The content: The experts’ methodology taught at this course goes beyond the number-crunching approaches of most consultants, to also include qualitative factors that are hard to define. This course demonstrates the practical application of state-of-the-art valuation methods specifically targeted towards high-risk and high-growth projects in the life science industry.
